



Date: 31 July 2024

To,
Corporate Relationship Department,
BSE Limited
PJ Towers, Dalal Street,
Mumbai 400001, MH

Stock Code: 542248

Subject: Press Release

Dear Sir/Madam,

This is further to our letter of the date intimating the Audited Standalone and Consolidated Financial Results Financial Results of the Company for the quarter and year ended 30 June 2024, enclosed is a copy of the Press Release on the same for your records.

The above information is being hosted on the Company's website www.deccanhealthcare.co.in in terms of Regulation 46 of the Listing Regulations, as amended.

You are requested to take the same on record.

Thanking You,
For and on behalf of
Deccan Health Care Limited


Vaishali Gagnani
Company Secretary &
Compliance Officer
(M. no A58408)
Encl: a/a

Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in

Deccan Health Care Limited Sees Robust Q1 FY25 Performance with 17.5% YoY Revenue and 18.4% YoY PAT Gains

Hyderabad, 31st July 2024: Deccan Health Care Limited (BSE: 542248), a leading nutraceuticals product company, with an aim to help consumers age gracefully, reduce the risk of disease, prevent disease, and live a better quality of life, today announced its Unaudited Financial Results for the Q1 FY25 period which ended 30th June 2024.

Key Highlights:

- ▷ **Product Launches:** OrganoWild Natural Iron Mango Slice, launched in May 2024, a unique product that helps boost daily iron intake and prevents anemia, especially in teenagers and women of childbearing age. The product has received strong consumer acceptance, leading to a regional distribution expansion.
- ▷ **Anemia Mukht Bharat Program Participation:** Expanding Collaboration: Deccan Health Care Limited is increasing its partnership with NGOs to support the Government of India's Anemia Mukht Bharat initiative and collaborating with MNC, Large IT Corporate bodies under their CSR initiatives for their employees.
- ▷ **Financial Performance:**
 - **Revenue:** In Q1 FY25, Deccan Health Care Limited achieved a revenue of ₹1,318.6 lakh. While this marks a 17.4% decrease from the previous quarter's ₹1,596.8 lakh, it reflects a positive YoY growth of 17.5%, up from ₹1,122.3 lakh in Q1 FY24. This growth showcases the company's resilience and strong market presence, demonstrating its ability to meet demand and drive sales over time.
 - **EBITDA:** The company's EBITDA increased to ₹87.0 lakh in Q1 FY25, a 29.8% rise from ₹67.0 lakh in Q4 FY24 by enhancing operational efficiency and effective cost optimization. Despite a revenue decrease, the EBITDA margin improved significantly from 4.2% to 6.6%. However, there was a slight YoY decline of 75 basis points from 7.3% in Q1 FY24, the company has maintained profitability and managed expenses effectively.
 - **PAT:** In Q1 FY25, the company's PAT surged to ₹36.9 lakh, a significant increase by 2.9x from ₹12.8 lakh in Q4 FY24, reflecting a robust improvement in net profitability. The PAT margin also showed considerable growth, rising from 0.8% to 2.8% on a QoQ basis.

Standalone Financial Performance for Q1 FY25 (₹ in Lakh):

Parameters	Q1 FY25	Q4 FY24	QoQ	Q1 FY24	YoY	FY24
Revenue	1,318.6	1,596.8	(17.4)%	1,122.3	17.5%	5,972.9
EBITDA	87.0	67.0	29.8%	82.5	5.5%	375.9
EBITDA Margin	6.6%	4.2%	+240 bps	7.3%	(75) bps	6.3%
PAT	36.9	12.8	2.9x	31.3	17.7%	152.2
PAT Margin	2.8%	0.8%	+199 bps	2.8%	-	2.5%

Commenting on the financial results, Dr. Minto Purshotam Gupta, Chairman & Managing Director of Deccan Health Care Limited said, "I am delighted to share that during the quarter our recent launch of OrganoWild Natural Iron Mango Slice has been met with strong consumer acceptance, allowing us to expand its regional distribution. This innovative product, aimed at boosting iron intake and preventing anemia, reflects our commitment to addressing important health needs, particularly for teenagers and women of childbearing age. We are also strengthening our efforts by partnering with NGOs and multinational corporations under their CSR initiatives to support the Anemia Mukh Bharat program and enhance employee well-being.

On the financial front, our performance has demonstrated resilience and growth. Despite a decrease in revenue from the previous quarter, we have seen impressive year-on-year growth, highlighting our ability to adapt and thrive in the market. Our focus on operational efficiency and cost optimization has significantly improved profitability, ensuring we continue to deliver value to our stakeholders. I am deeply grateful for the support of our dedicated team and partners, and I look forward to building on this momentum as we strive for continued excellence."

About Deccan Health Care Limited (BSE: 542248):

Deccan Health Care Limited, established in 1996, is a leading nutraceutical company committed to helping consumers age gracefully and enhance their overall well-being. With a focus on innovation, supply chains, and brand equity, the company consistently delivers superior value to its customers. Popular for its Fast-Moving Consumer Healthcare products, including food pills and meals, Deccan Health Care Limited addresses 52+ wellness goals, preventing over 200+ diseases. The success of the BE YOUNG brand, particularly through e-commerce, reflects the company's dedication. Moreover, the international expansion with the STAY YOUNG brand further demonstrates its dynamic approach. Deccan Health Care Limited stands out as a positive force in the nutraceuticals industry, prioritizing consumer health and sustained growth.

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential, and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

DECCAN HEALTH CARE LIMITED CIN: L72200TG1996PLC024351	
Dr. Minto Purshotam Gupta Chairman & Managing Director E: cmd@deccanhealthcare.co.in W: www.deccanhealthcare.co.in	Mr. Ritesh Shashiprakash Singh Investor Relations Consultant, Rik Capital M: +91 83293 85762 E: ritesh.singh@rikcapital.in W: www.rikcapital.in